Brief: Aldeyra Therapeutics Inc Says New Drug Application Resubmission Is Anticipated Mid‑2025
05/05/2025 23:36
May 5 (Reuters) - Aldeyra Therapeutics Inc ALDX.O: ALDEYRA THERAPEUTICS INC - NEW DRUG APPLICATION RESUBMISSION IS ANTICIPATED MID‑2025 ALDEYRA THERAPEUTICS ACHIEVES PRIMARY ENDPOINT IN PHASE 3 DRY EYE DISEASE CHAMBER TRIAL OF REPROXALAP AND PLANS NDA RESUBMISSION Source text: ID:nBw1zhPK3a Further company coverage: ALDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug